Abstract
Poor adherence to medicines in clinical trials can undermine the value of the trials; for example, by compromising estimates of the benefits and risks of a medicine. In this article, we highlight such consequences and also discuss approaches to tackle this problem.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Panic or peace – prioritising infant welfare when medicating feverish infants: a grounded theory study of adherence in a paediatric clinical trial
BMC Pediatrics Open Access 11 April 2022
-
Examining study participants’ decision-making and ethics-related experiences in a dietary community randomized controlled trial in Malawi
BMC Medical Ethics Open Access 03 December 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Marrazzo, J.M. et al. Tenofovir-based pre-exposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 372, 509–518 (2015).
Blaschke, T.F. et al. Adherence to medications. Insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu. Rev. Pharmacol. Toxicol. 52, 275–301 (2012).
Bhatia, S. et al. Non adherence to oral mercaptopurine and risk of relapse in Hispanic and non-Hispanic white children with acute lymphoblastic leukaemia. J. Clin. Oncol. 17, 2094–2101 (2012).
Marin, D. et al. Adherence is a critical factor for achieving molecular responses in patients with chronic myeloid leukaemia who achieve complete cytogenic responses on imatinib. J. Clin. Oncol. 28, 2381–2388 (2010).
Corral, G. et al. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension 66, 742–749 (2015).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Related links
FURTHER INFORMATION
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
Rights and permissions
About this article
Cite this article
Breckenridge, A., Aronson, J., Blaschke, T. et al. Poor medication adherence in clinical trials: consequences and solutions. Nat Rev Drug Discov 16, 149–150 (2017). https://doi.org/10.1038/nrd.2017.1
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.1
This article is cited by
-
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Nature Reviews Drug Discovery (2023)
-
Panic or peace – prioritising infant welfare when medicating feverish infants: a grounded theory study of adherence in a paediatric clinical trial
BMC Pediatrics (2022)
-
The need for increased pragmatism in cardiovascular clinical trials
Nature Reviews Cardiology (2022)
-
Designing Drug Regimens that Mitigate Nonadherence
Bulletin of Mathematical Biology (2022)
-
Examining study participants’ decision-making and ethics-related experiences in a dietary community randomized controlled trial in Malawi
BMC Medical Ethics (2021)